6 consecutive boards Zhen Yao Pharmaceutical Industry: The company's stock price has risen sharply and continuously in the short term, with the risk of a rapid decline.

Tianjin Pharmaceutical Industry announced on April 3rd that the company's stock price has risen significantly in the short term, with a risk of rapid decline. From March 26 to April 3, 2026, the company's stock price hit the limit for six consecutive trading days, with a cumulative increase of 76.01%. The turnover rate on the most recent trading day has noticeably increased, indicating continued trading risk. There is a risk of market sentiment overheating and irrational speculation, as the company's fundamentals have not undergone major changes and there is a potential for rapid decline. At the same time, Tianjin Pharmaceutical Industry stated that the company's research and development mainly focuses on generic drugs and it does not have any innovative drug projects under research. The company has noticed that the market has categorized it as an innovative drug concept and is speculating on it. However, the company primarily focuses on generic drugs in its research and development, with no ongoing innovative drug projects, indicating a clear misunderstanding in the speculation.